Skip to main content

Table 4 Comparison outcome of therapeutic dose group and sub-therapeutic dose group

From: Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis

Variable TPDA group sub-TPDA group P value
Number 23 38
Female 9 (39.1) 22 (57.9) 0.155
Age 57.4 (17.3) 54.3 (13.7) 0.466
Acute DVT 15 (65.2) 24 (63.2) 0.871
Subacute DVT 8 (34.8) 14 (36.8)
Thrombolytic treatment
 Median infusion rates 10,000 U/hour 2.5 (0.8–4.2) 2.5 (1.7–5) 0.891
 Median dose, 10,000 U 240 (60–1080) 240 (80–480) 0.456
 Median duration time, day 4 (2–12) 4 (2–14) 0.131
Balloon 3 (13.0) 3 (7.9) 1.000
Stent 1 (4.3) 6 (15.8) 0.236
Thrombosis degree
 Undissolved 3 (13.0) 2 (5.3) 0.665
 Partial 15 (65.2) 28 (73.7)
 Complete 5 (21.7) 8 (21.1)
Clinical improvement 20 (87.0) 37 (97.4) 0.146
Decreased mid-thigh circumference, cm 2.1 (2.4) 2.4 (1.8) 0.716a
Decreased mid-crus circumference, cm 2.2 (1.9) 3.1 (2.2) 0.268b
Bleeding
 Major bleeding 0 (0) 0 (0) 1.000
 Minor bleeding 1 (4.3) 4 (10.5) 0.641
  1. Note: w = week, m = month, DVT = deep venous thrombosis, a10 cm from lower margin of the tibial tuberosity; b15 cm from upper margin of the patella